Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers

被引:12
作者
Sood, Akshay [1 ]
Cole, Daniel [1 ]
Abdollah, Firas [1 ]
Eilender, Ben [1 ]
Roumayah, Zade [1 ]
Deebajah, Mustafa [1 ]
Dabaja, Ali [1 ]
Alanee, Shaheen [1 ]
机构
[1] Henry Ford Hosp, Vattikuti Urol Inst, 2799 W Grand Blvd, Detroit, MI 48202 USA
关键词
Prostate cancer; Bladder cancer; Renal cancer; Programmed death; Side effects; Immune checkpoint therapy; LEAN BODY-MASS; ANTI-PD-1; ANTIBODY; CLINICAL ACTIVITY; CELL-CARCINOMA; SAFETY; IMMUNOTHERAPY; BLOCKADE; B7-H1; PREVALENCE; MANAGEMENT;
D O I
10.1007/s11934-018-0819-7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of Review Immune checkpoint therapy has grown in prominence in the last few decades and is being increasingly utilized in treatment of advanced cancers. Although information on toxicities of these drugs is forthcoming, not much is known regarding the toxicity profile of these drugs from a sexual function standpoint. We undertook the current review to appraise the literature for endocrine/sexual side effects of anti-PD-1/PD-L1 and anti-CTLA-4 therapy. Recent Findings Our review included 32 articles and focused primarily on the programmed death (PD) pathway. We found that endocrine side effects after anti-PD-1/PD-L1 therapy are relatively rare, with hypothyroidism (range < 1 to 40%) and hypophysitis (range < 1 to 10%) being the two most common. None of the studies specifically commented on the infertility or sexual side effects of these drugs. However, two studies evaluating biochemical profiles of patients undergoing therapy with ipilimumab (a CTLA-4 inhibitor) or combination therapy (CTLA-4 + PD-1/PD-L1 inhibitors) noted that about < 1 to similar to 60% of the patients developed hypogonadotropic hypogonadism. None of the studies provided information regarding clinically meaningful sexual health endpoints such as libido, erectile function assessments, or sexual function-related quality of life. Summary Endocrine side effects, although uncommon, are important and unique side effects of immune checkpoint therapy because they are often complex and can be life threatening. While side effects on sexual health may not be life threatening, they are lifestyle limiting. Thus, long-term follow-up, post-marketing surveillance, and future studies will need to elucidate the true rates of endocrine/sexual side effects and the mechanisms underlying them. This will aid in better counseling of the patients, as more of them undergo these novel immune checkpoint inhibitor therapies.
引用
收藏
页数:9
相关论文
共 50 条
[1]  
Alexander Walter, 2016, P T, V41, P185
[2]   PSYCHOLOGICAL INTERVENTIONS FOR CANCER-PATIENTS TO ENHANCE THE QUALITY-OF-LIFE [J].
ANDERSEN, BL .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1992, 60 (04) :552-568
[3]   A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now [J].
Bellmunt, Joaquin ;
Powles, Thomas ;
Vogelzang, Nicholas J. .
CANCER TREATMENT REVIEWS, 2017, 54 :58-67
[4]   Semen cryopreservation, utilisation and reproductive outcome in men treated for Hodgkin's disease [J].
Blackhall, FH ;
Atkinson, AD ;
Maaya, MB ;
Ryder, WDJ ;
Horne, G ;
Brison, DR ;
Lieberman, BA ;
Radford, JA .
BRITISH JOURNAL OF CANCER, 2002, 87 (04) :381-384
[5]   Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].
Brahmer, Julie R. ;
Drake, Charles G. ;
Wollner, Ira ;
Powderly, John D. ;
Picus, Joel ;
Sharfman, William H. ;
Stankevich, Elizabeth ;
Pons, Alice ;
Salay, Theresa M. ;
McMiller, Tracee L. ;
Gilson, Marta M. ;
Wang, Changyu ;
Selby, Mark ;
Taube, Janis M. ;
Anders, Robert ;
Chen, Lieping ;
Korman, Alan J. ;
Pardoll, Drew M. ;
Lowy, Israel ;
Topalian, Suzanne L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175
[6]   Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis [J].
Brouard, S ;
Otterbein, LE ;
Anrather, J ;
Tobiasch, E ;
Bach, FH ;
Choi, AMK ;
Soares, MP .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) :1015-1025
[7]   Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade Insights into Pathogenesis from an Autopsy Series [J].
Caturegli, Patrizio ;
Di Dalmazi, Giulia ;
Lombardi, Martina ;
Grosso, Federica ;
Larman, H. Benjamin ;
Larman, Tatianna ;
Taverna, Giacomo ;
Cosottini, Mirco ;
Lupi, Isabella .
AMERICAN JOURNAL OF PATHOLOGY, 2016, 186 (12) :3225-3235
[8]   Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future [J].
Chen, Lieping ;
Han, Xue .
JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (09) :3384-3391
[9]   Cancer Immunotherapy [J].
Couzin-Frankel, Jennifer .
SCIENCE, 2013, 342 (6165) :1432-1433
[10]   The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial [J].
Dalton, James T. ;
Barnette, Kester G. ;
Bohl, Casey E. ;
Hancock, Michael L. ;
Rodriguez, Domingo ;
Dodson, Shontelle T. ;
Morton, Ronald A. ;
Steiner, Mitchell S. .
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2011, 2 (03) :153-161